Today we look back on a small oncology play that remains a speculative but attractive Tier 4 biotech concern. I have had a few questions on this busted IPO of late, so I thought we would revisit this name today.
Today we look back on a small oncology play that remains a speculative but attractive Tier 4 biotech concern. I have had a few questions on this busted IPO of late, so I thought we would revisit this name today.
